Mizuho resumed coverage of Healthpeak Properties with a Buy rating and $22 price target. The shares have underperformed healthcare real estate investment trusts year-to-date as investors remain concerned about capital allocation and value creation, challenging fundamentals in life sciences and limited growth opportunities in the company’s medical office segment, the analyst tells investors in a research note. However, the firm sees several catalysts during the next few quarters for Healthpeak to re-rate, including selling assets and buying back stock, and an inflection in life science fundamentals in the second half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOC:
- Crocs initiated, Bill downgraded: Wall Street’s top analyst calls
- Healthpeak Properties upgraded to Buy from Underperform at BofA
- Healthpeak Properties price target raised to $26 from $22 at Baird
- Healthpeak Properties resumed with an Equal Weight at Wells Fargo
- Healthpeak Properties resumed with an Outperform at RBC Capital
